PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 2, 20267 citations

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

View Full Paper
LTLambros TselikasSSSandrine SusiniMTMatthieu Texier

Key Points

  • To investigate the safety and efficacy of combined intratumoural anti-CTLA4 with intravenous anti-PD1 therapy.
  • Evaluated macrophage numbers in tumor environments as a factor for treatment efficacy.
  • Examined the safety profile of combined therapies.
  • Increased M2 macrophage numbers correlated with better treatment outcomes.
  • Treatment exhibited a favorable safety profile.

Abstract

M2 macrophage numbers are prerequisites for efficacy of combined anti-CTLA4 and anti-PD1.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tselikas et al. (2026) studied this question.

synapsesocial.com/papers/69f5945c71405d493afff2c9https://doi.org/10.1038/s41586-026-10341-w
Ask AI
Helpful
Bookmark
Share
View Full Paper